Table 2.
CYP7B1 expression according to IHC score.
| CYP7B1 | p-Value | ||
|---|---|---|---|
| Negative (n = 251) | Positive (n = 139) | ||
| Age (years), median (Q1–Q3) | 71 (65–76) | 68 (63–71) | <0.01 |
| PSA (ng/mL), median (Q1–Q3) | 6.1 (3.53–9.6) | 7.2 (5.4–11) | <0.01 |
| Fasting glucose (mg/dL), median (Q1–Q3) | 96 (87–109) | 97 (88–111) | 0.9 |
| Total cholesterol (mg/dL), median (Q1–Q3) | 181.5 (156–210) | 190.5 (165.5- 218) | 0.1 |
| Triglycerides (mg/dL), median (Q1–Q3) | 100 (68–137) | 103 (72–146) | 0.9 |
| Diabetes, n (%) | 59 (23.5) | 33 (23.74) | 0.95 |
| Group, n (%) | <0.01 | ||
| BPH | 94 (37.45) | 10 (7.19) | |
| PC | 157 (62.55) | 129 (92.81) | |
| ISUP Gleason score in PC patients, n (%) | 0.25 | ||
| 1 | 49 (31.21) | 33 (25.58) | |
| 2 | 63 (40.13) | 47 (36.43) | |
| 3 | 34 (21.66) | 32 (24.81) | |
| 4 | 4 (2.55) | 10 (7.75) | |
| 5 | 7 (4.46) | 7 (5.43) | |
| Pathological stage in PC patients, n (%) | 0.04 | ||
| T2 | 111 (70.70) | 86 (66.67) | |
| T3 | 33 (21.02) | 20 (15.50) | |
| T4 | 13 (8.28) | 23 (17.83) | |
| Classification risk of PC, n (%) | 0.2 | ||
| Low risk | 56 (35.67) | 44 (34.11) | |
| Intermediate risk | 74 (47.13) | 52 (40.31) | |
| High risk | 27 (17.20) | 33 (25.58) | |
| Ki-67-positive score, n (%) | 31 (12.35) | 22 (15.83) | 0.3 |
| AR-positive score, n (%) | 110 (43.82) | 72 (51.80) | 0.1 |
| PSMA-positive score, n (%) | 71 (28.29) | 77 (55.40) | <0.01 |
| IR-α-positive score, n (%) | 132 (52.59) | 127 (91.37) | <0.01 |
| IR-β-positive score, n (%) | 4 (1.59) | 19 (13.67) | <0.01 |
| IGF-1R-positive score, n (%) | 36 (14.34) | 28 (20.14) | 0.1 |
| ATPLy-positive score, n (%) | 92 (36.65) | 95 (68.35) | <0.01 |
| SRSF-1-positive score, n (%) | 99 (39.44) | 89 (64.03) | <0.01 |
| CPT1-a-positive score, n (%) | 33 (13.15) | 32 (23.02) | 0.01 |
| SCD-1-positive score, n (%) | 39 (15.54) | 26 (18.71) | 0.4 |
| SREBP1-positive score, n (%) | 70 (27.89) | 26 (18.71) | 0.04 |
| FAS-positive score, n (%) | 111 (44.22) | 101 (72.66) | <0.01 |
| ACC-1-positive score, n (%) | 69 (27.49) | 75 (53.96) | <0.01 |
IHC = immunohistochemistry; BPH = benign prostatic hyperplasia; PC = prostate cancer; Q1–Q3 = interquartile range; CYP7B1 = cytochrome 7B1; AR = androgenic receptor; PSA = prostate-specific antigen; IR = insulin receptor; IGF-1R = insulin-like growth factor-1 receptor; PSMA = prostate-specific membrane antigen; SRSF-1 = aerine/arginine-rich splicing factor 1; FAS = fatty acid synthase; CPT-1a = carnitine palmitoyltransferase 1a; SCD-1 = stearoyl-CoA desaturase-1; SREBP-1 = sterol regulatory element-binding protein-1; ACC-1 = acetyl-CoA carboxylase-1.